What Comes Next Theres a lot we still dont know about whats next for this marketplaceand to borrow a line from the Hims ad, there are aspects of the system that remain broken
Trimi's compounded semaglutide uses the same active pharmaceutical ingredient but is prepared per individual prescription by a 503A compounding pharmacy and isn't reviewed by the FDA for safety, effectiveness, or quality before marketing
doi: 10.1056/NEJMoa1203858 264 SattarNMcGuireDKPavoIWeerakkodyGJNishiyamaHWieseRJet al
Mattingly says theres no evidence of significant side effects from stopping abruptly versus tapering off more slowly
Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics
Thats not where the risk-benefit lies. Given that health insurance wont cover GLP-1s if you arent obese, dont have type 2 diabetes, or arent overweight with cardiovascular disease, the cost can add up for years before you know whether the spend was really worth it